Catalyst Pharmaceuticals Inc. (Catalyst Pharmaceuticals), is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating neuromuscular and neurological diseases.
Catalyst is currently developing amifampridine phosphate (with the proposed tradename of Firdapse®) for the treatment of Lambert - Eaton Myasthenic Syndrome (LEMS). LEMS is a rare, autoimmune, neuromuscular disorder in which the body attacks and
interferes with the communication between nerve and muscle cells primarily causing progressively severe muscle weakness and fatigue.
Catalyst has completed a pivotal phase III, multi-centered clinical trial that showed amifampridine phosphate to be safe and effective in the treatment of patients with LEMS and is currently conducting a second, similar trial. Additionally, Catalyst is currently conducting a separate clinical trial of amifampridine phosphate in patients with Congenital Myasthenic Syndromes (CMS). Catalyst is also preparing to launch an additional clinical trial amifampridine phosphate in patients with MuSK Positive Myasthenia Gravis (MuSK-MG).
Expanded Access Program
Catalyst Pharmaceuticals has an Expanded Access Program (EAP) for amifampridine phosphate, which is an open-label pre-approval safety study where patients who are diagnosed with LEMS or certain types of Congenital Myasthenic Syndromes (CMS) and meet the inclusion and exclusion criteria can receive amifampridine phosphate (at no cost) when a patient's physician determines this investigational medication can help improve the patient’s condition. For questions about the EAP please contact us at our toll free telephone number: 1-844-347-3277 Read More
Catalyst Pharmaceuticals is also studying amifampridine phosphate in other neurological orphan indications like MuSK Positive Myasthenia Gravis (MuSK-MG).
Other pipeline programs include CPP-115, which is under investigation in several neurological conditions such as epilepsy, Tourette’s disorders and infantile spasms. Read More